Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer

Bicycle toxin conjugates (BTCs) are a promising new class of molecules for targeted delivery of toxin payloads into tumors. Herein we describe the discovery of BT8009, a Nectin-4 targeting BTC currently under clinical evaluation. Nectin-4 is overexpressed in multiple tumor types and is a clinically validated target for selective delivery of cytotoxic payloads. A Nectin-4 targeting bicyclic peptide was identified by phage display, which showed highly selective binding for Nectin-4 but suffered from low plasma stability and poor physicochemical properties. Multiparameter chemical optimization involving introduction of non-natural amino acids resulted in a lead Bicycle that demonstrated high affinity for Nectin-4, good stability in biological matrices, and a much-improved physicochemical profile. The optimized Bicycle was conjugated to the cytotoxin Monomethyl auristatin E via a cleavable linker to give the targeted drug conjugate BT8009, which demonstrates potent anticancer activity in in vivo rodent models.

Automated summary

Bicycle toxin conjugates (BTCs) are a promising new class of molecules that can deliver toxins to tumor cells effectively. BT8009 is a Nectin-4 targeting BTC that has been optimized through chemical optimization. The optimized bicyclic peptide shows highly selective binding to Nectin-4, good plasma stability, and improved physicochemical properties. The optimized bicycle is conjugated to the cytotoxin Monomethyl auristatin E to form the targeted drug conjugate BT8009, which exhibits potent anticancer activity in vivo rodent models.